Metalloestrogens

17th Tuesday, 2015  |   Uncategorized  |  no comments

metalloestrogen The world abounds with substances that affect hormone balance. It is widely accepted that that there are many organic substances that affect hormone activity in the body. For example, soy has estrogen-like qualities and ginseng acts as an adrenal adaptogen. We can use these organic substances in ways that are beneficial to the body. On the other hand, organic substances like phthalates, PCBs and BPA mimic estrogens in a negative way. They create a burden of too much estrogen activity in the body. Researchers are now turning to inorganic sources of hormone disruption. In 2006, Darbre published a paper that identified many metals that have an effect on estrogen receptors. These effects include: altering gene expression, estrogenic activity, and displacing estrogens from estrogen receptors. Metals that have been identified to exert an influence on estrogen receptors include aluminum, antimony, arsenite, barium, cadmium, chromium, cobalt, copper, lead, mercury, nickel, selenite, tin, and vanadate. These metals are referred to as metalloestrogens. The paper also identified metalloestrogen activity at progesterone, testosterone and glucocorticoid (hydrocortisone-like) receptors. For example, cadmium has been shown to produce testosterone activity, displace testosterone from testosterone receptors and affect gene changes. Darbre concludes that all steroid hormone receptors may be affected. Some metalloestrogens are essential minerals. Cobalt, chromium, copper, and nickel are all needed in trace amounts for normal human body function. When the amounts of these minerals exceed the amount needed by the body, they begin to interfere with the hormone receptors. Other metalloestrogens, such as cadmium, aluminum, and lead, are not needed by the body in any amount. Cadmium is problematic because the human body doesn’t have an enzyme system to eliminate it once we are exposed. Making matters worse, the kidneys reabsorb cadmium rather than eliminate it. The amount of cadmium in our bodies continues to increase as we age. Common sources of cadmium, outside of industrial uses, include cigarette smoke and certain foods due to cadmium pollution in our environment. Cadmium may be a trigger for endometriosis. Several studies point to an association between the presence of cadmium in the body and endometrial tissue proliferation. One especially interesting study found melatonin was able to block the estrogenic effect of cadmium in endometrial tissue. Lead acts as a metalloestrogen by occupying hormone receptors. Unsurprisingly, lead contributes to a number of health conditions. The Environmental Protection Agency (EPA) recognizes lead can cause a number of problems for women. After menopause, increased levels of lead in the body increase one’s risk for hypertension, atherosclerosis, reduced kidney function, and decreased cognitive functioning with symptoms similar to dementia. Osteoporosis, another condition common in menopause, can cause lead to be released into the body as bone breaks down. Those of us who have been exposed to lead paints and leaded gasoline have higher levels of lead in our bones, causing higher levels of lead in our bodies as lead is released from our bones. To read more about lead, click this link: http://www.womensinternational.com/newsletter/article_GetTheLeadOut.html. As research expands and we dig deeper into hormone balance issues, more information emerges to help us solve the riddle of hormone imbalance. The effects of metalloestrogens are not always considered by busy practitioners. Furthermore, many are not trained to help reduce the body’s load of metalloestrogens. Two medical groups that focus on reducing metalloestrogens in the body are the International College of Integrated Medicine (www.icimed.com) and the American College for Advancement in Medicine (www.acam.org). References: Darbre, P.D. ‘Metalloestrogens: An Emerging Class of Inorganic Xenoestrogens With Potential to Add to the Oestrogenic Burden of the Human Breast.’ Journal of Applied Toxicology 2006; DOI:10.1002/jat.1135. http://epa.gov/aging/factsheets/weh-rd.html Silva N, Tennekoon K, Senanayake H, Samarakoon S. Metalloestrogen cadmium stimulates proliferation of stromal cells derived from the eutopic endometrium of women with endometriosis.Taiwan J Obstet Gynecol. 2013 Dec;52(4):540-5. L.W. Jackson, M.D. Zullo and J.M. Goldberg The association between heavy metals, endometriosis and uterine myomas among premenopausal women: National Health and Nutrition Examination Survey 1999 – 2002 Human Reproduction Vol 23 No. 3 pp 679-687, 2008 http://chemicaloftheday.squarespace.com/most-controversial/2014/9/4/metalloestrogens.html

Phellinus Linteus Extract Induces Autophagy and Synergizes With 5-Fluorouracil to Inhibit Breast Cancer Cell Growth

11th Wednesday, 2015  |   Breast Cancer, Cancer  |  no comments

imagespic03

ABSTRACT
Phellinus linteus (PL) is a medicinal mushroom due to its several biological properties, including anticancer activity. However, the mechanisms of its anticancer effect remain to be elucidated. We evaluated the inhibitory effects of the ethanolic extract from the PL combined with 5-FU on MDA-MB-231 breast cancer cell line and to determine the mechanism of cell death. Individually, PL extract and 5-FU significantly inhibited the proliferation of MDA-MB-231 cells in a dose-dependent manner. PL extract (30 mg/mL) in combination with 5-FU (10 ?g/mL) synergistically inhibited MDA-MB-231 cells by 1.8-fold. PL did not induce apoptosis, as demonstrated by the DNA fragmentation assay, the sub-G1 population, and staining with annexin V-FITC and propidium iodide. The exposure of MDA-MB-231 cells to PL extracts resulted in several confirmed characteristics of autophagy, including the appearance of autophagic vacuoles revealed by monodansylcadaverine staining, the formation of acidic vesicular organelles, autophagosome membrane association of microtubule-associated protein light chain 3 (LC3) characterized by cleavage of LC3 and its punctuate redistribution, and ultrastructural observation of autophagic vacuoles by transmission electron microscopy. We concluded that PL extracts synergized with low doses of 5-FU to inhibit triple-negative breast cancer cell growth and demonstrated that PL extract can induce autophagy-related cell death.

INTRODUCTION
Metastasis is the main cause of therapeutic failure and death for breast cancer patients. To improve the prognosis of these patients, adjuvant chemotherapy is often used in a variety of clinical situations. However, the toxicity of these chemotherapeutic agents to normal tissues has been a major obstacle to successful cancer treatment. The antimetabolite 5-fluorouracil (5-FU) is a major chemotherapeutic agent for breast cancer treatment (1), and the mechanism of its cytotoxicity is the misincorporation of fluoronucleotides into DNA and RNA, thus inhibiting the normal function of these nucleic acids. Therefore, the development of less toxic and more effective anticancer drugs that can be used in combination with existing therapeutic agents may enhance treatment outcomes and reduce the toxicity of the existing drugs. Fungi have been intensively investigated as anticancer agents because they are able to modulate the immune responses against cancers with very low toxic potential (2) and thus represent a potentially important new source of anticancer agents.

Phellinus linteus (PL), a basidiomycete fungus, is commonly called Sangwhang in Taiwan and has gained significant recognition as a medicinal mushroom in traditional Oriental medicine (3). Studies have demonstrated that the extracts from the fruiting bodies or mycelium of PL not only stimulate immune function but also suppress tumor growth and metastasis in vitro (3–6). In vivo studies have also demonstrated that PL extracts can cause tumor regression (7). However, the mechanisms of its anticancer effect remain to be elucidated. Several studies have demonstrated that PL inhibits the metastasis of melanoma cells in mice through the regulation of urokinase-type plasminogen activator (8) and suppresses the growth of lung, prostate, and colon cancer cells by inducing cell cycle arrest and apoptosis (9–13). PL was also demonstrated to suppress the growth, angiogenesis, and invasion through the inhibition of AKT phosphorylation in breast cancer cells (14) and through the inhibition of Wnt/?-catenin signaling in colon cancer cells (15).

There are 3 reported cases of dramatically regressed cancers after treatment with PL, including 2 cases from Japan: 1 hormone-refractory prostate cancer with bone metastasis (16) and 1 hepatocellular carcinoma with multiple lung metastases (17); the third case occurred in Korea and was a hepatocellular carcinoma with skull metastasis (18). All of these cases suggested a linear relationship between the usage of PL and tumor regression. In addition, PL inhibited the growth of various prostate cancer cell lines without toxic effects on normal prostate epithelial cells (10) and reduced tumor growth and pulmonary metastasis without toxic effects in mice (6). Moreover, PL have been shown to synergize with doxorubicin in its noncytotoxic dose range to induce apoptosis in prostate and lung cancer cells (9,10), suggesting that PL can also function as an adjunct in cancer treatment to reduce the doses of conventional chemotherapeutic drugs and limit cytotoxicity.

Anticancer therapeutics activate several signal transduction pathways that regulate programmed cell death in cancer cells. Understanding the mechanisms of programmed cell death and designing specific therapeutic approaches to induce cell death in cancer cells are critical for cancer treatment (19). There are 2 morphologically distinct forms of programmed cell death: apoptosis and autophagic cell death. Traditional cancer therapies primarily aim to enhance apoptosis. However, cancer cells are often deficient in the induction of apoptosis, which results in resistance to most anticancer therapies (19,20). Thus, understanding the regulation and significance of the nonapoptotic form of programmed cell death in cancer therapy is critical to optimizing cancer therapy. Autophagic cell death is characterized by the massive degradation of essential organelles such as mitochondria. These intracellular contents are sequestered in a membrane-bound vesicle known as an autophagosome and then degraded following lysosomal fusion (21–23). Evidences indicate that autophagy plays a significant role in cancer initiation and progression. Nearly all therapeutic modalities currently used in cancer therapy, including cytotoxic chemotherapy, radiation, kinase inhibitors, and hormone therapy, can induce autophagy in cancer cells (21–23). Multiple studies have demonstrated that there is molecular cross-talk between autophagy and apoptosis (24), that the same stimulus can simultaneously induce both apoptosis and autophagy (25), and that 2 processes can be mutually exclusive, with each acting as a backup for the other (23).

PL has been shown to have anticancer effects in vitro and in vivo (3–7), but the underlying mechanism remained to be elucidated. PL was reported to induce apoptosis in various types of cancer, including colon, lung, prostate and melanoma cells (9–13,34). However, our study revealed that PL did not induce apoptosis detected by the DNA fragmentation assay, sub-G1 population, and annexin V-FITC/PI double staining in breast cancer cells.

Collins et al. showed that PL and the anti-cancer drug doxorubicin (Dox) did not induce apoptosis in prostate cancer cells at relatively low doses; however, the combination treatment with low doses of PL and Dox resulted in a synergistic effect on the induction of apoptosis (10). Guo et al. demonstrated that PL modulated cell cycle arrest at a low dose and induced apoptosis at a high dose in lung cancer cells (9). Taken together, the dose of PL used in this study may be the major reason for the differences from the previous studies. In addition, the mycelial species, extraction method (hot water vs. ethanolic), culture conditions and cell lines may affect the results.

Source
Lee W-y, Hsu K-F, Chiang T-A. Nutrition and Cancer. Volume 67, Issue 2, 2015. DOI: 10.1080/01635581.2015.989374
References
1. Wyatt MD and Wilson DM, III: Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66, 788–799, 2009.
2. Sullivan R, Smith JE, and Rowan NJ: Medicinal mushrooms and cancer therapy: translating a traditional practice into Western medicine. Perspect Biol Med 49, 159–170, 2006.
3. Zhu T, Kim SH, and Chen CY: A medicinal mushroom: Phellinus linteus. Curr Med Chem 15, 1330–1335, 2008.
4. Kim GY, Lee JY, Lee JO, Ryu CH, Choi BT, : Partial characterization and immunostimulatory effect of a novel polysaccharide-protein complex extracted from Phellinus linteus. Biosci Biotechnol Biochem 70, 1218–1226, 2006.
5. Han SB, Lee CW, Kang JS, Yoon YD, Lee KH, : Acidic polysaccharide from Phellinus linteus inhibits melanoma cell metastasis by blocking cell adhesion and invasion. Int Immunopharmacol 6, 697–702, 2006.
6. Han SB, Lee CW, Jeon YJ, Hong ND, Yoo ID, : The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis. Immunopharmacology 41, 157–164, 1999.
7. Tsuji T, Du W, Nishioka T, Chen L, Yamamoto D, : Phellinus linteus extract sensitizes advanced prostate cancer cells to apoptosis in athymic nude mice. PLoS One 5, e9885, 2010.
8. Lee HJ, Lee HJ, Lim ES, Ahn KS, Shim BS, : Cambodian Phellinus linteus inhibits experimental metastasis of melanoma cells in mice via regulation of urokinase type plasminogen activator. Biol Pharm Bull 28, 27–31, 2005.
9. Guo J, Zhu T, Collins L, Xiao ZX, Kim SH, : Modulation of lung cancer growth arrest and apoptosis by Phellinus Linteus. Mol Carcinog 46, 144–154, 2007.
10. Collins L, Zhu T, Guo J, Xiao ZJ, and Chen CY: Phellinus linteus sensitises apoptosis induced by doxorubicin in prostate cancer. Br J Cancer 95, 282–288, 2006.
11. Zhu T, Guo J, Collins L, Kelly J, Xiao ZJ, : Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells. Br J Cancer 96, 583–590, 2007.
12. Li G, Kim DH, Kim TD, Park BJ, Park HD, : Protein-bound polysaccharide from Phellinus linteus induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells. Cancer Lett 216, 175–181, 2004.
13. Park HJ, Choi SY, Hong SM, Hwang SG, and Park DK: The ethyl acetate extract of Phellinus linteus grown on germinated brown rice induces G0/G1 cell cycle arrest and apoptosis in human colon carcinoma HT29 cells. Phytother Res 24, 1019–1026, 2010.
14. Sliva D, Jedinak A, Kawasaki J, Harvey K, and Slivova V: Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling. Br J Cancer 98, 1348–1356, 2008.
15. Song KS, Li G, Kim JS, Jing K, Kim TD, : Protein-bound polysaccharide from Phellinus linteus inhibits tumor growth, invasion, and angiogenesis and alters Wnt/beta-catenin in SW480 human colon cancer cells. BMC Cancer 11, 307, 2011.
16. Shibata Y, Kurita S, Okugi H, and Yamanaka H: Dramatic remission of hormone refractory prostate cancer achieved with extract of the mushroom, Phellinus linteus. Urol Int 73, 188–190, 2004.
17. Nam SW, Han JY, Kim JI, Park SH, Cho SH, : Spontaneous regression of a large hepatocellular carcinoma with skull metastasis. J Gastroenterol Hepatol 20, 488–492, 2005. [CrossRef], [PubMed], [Web of Science ®]
18. Kojima H, Tanigawa N, Kariya S, Komemushi A, Shomura Y, : A case of spontaneous regression of hepatocellular carcinoma with multiple lung metastases. Radiat Med 24, 139–142, 2006.
19. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, : Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 615, 47–79, 2008.
20. Johnstone RW, Ruefli AA, and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153–164, 2002.
21. Kondo Y and Kondo S: Autophagy and cancer therapy. Autophagy 2, 85–90, 2006.
22. Kung CP, Budina A, Balaburski G, Bergenstock MK, and Murphy M: Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr 21, 71–100, 2011. [CrossRef], [PubMed], [Web of Science ®]
23. Maycotte P and Thorburn A: Autophagy and cancer therapy. Cancer Biol Ther 11, 127–137, 2011.
34. Park HJ, Han ES, and Park DK: The ethyl acetate extract of PGP (Phellinus linteus grown on Panax ginseng) suppresses B16F10 melanoma cell proliferation through inducing cellular differentiation and apoptosis. J Ethnopharmacol 132, 115–121, 2010.

Correlation between pretherapeutic d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer.

9th Friday, 2015  |   Cancer  |  no comments

blood Source Tomimaru Y, Yano M, Takachi K, et al. Dis Esophagus. 2008;21(4):281-7. doi: 10.1111/j.1442-2050.2007.00758.x. Neoadjuvant chemotherapy may improve survival of responders in esophageal cancer patients but is useless and harmful in non-responders. Thus, it is important to predict the effect of the chemotherapy, and that any predictor must be applicable clinically. The aim of this study is to examine the correlation between pretherapeutic hypercoagulopathy as determined by plasma d-dimer levels and response to chemotherapy. In 71 patients with esophageal cancer who underwent neoadjuvant chemotherapy (cisplatin, adriamycin and 5-fluorouracil) followed by surgery, plasma d-dimer levels were measured before chemotherapy and the clinical and pathological responses to chemotherapy were assessed at 4 weeks after therapy (after surgery). Pretherapeutic plasma d-dimer level was significantly lower in clinical responders (complete response/partial response [CR/PR]; 0.62 +/- 1.10 microg/mL, mean +/- SD) than in non-responders (no change/progressive disease [NC/PD]; 1.15 +/- 1.08 microg/mL, P = 0.0491), and in pathological responders (Grade 1b-3; 0.62 +/- 1.11 microg/mL) and non-responders (Grade 0-1a; 1.15 +/- 1.05 microg/mL, P = 0.0107). The optimal cut-off level of the plasma d-dimer levels for predicting clinical and pathological responses was 0.6 microg/mL. Then, sensitivity and specificity for the prediction of CR/PR were 68% and 73%, and those for Grade 1b-3 were 91% and 69%, respectively. Our results suggested that pretherapeutic plasma d-dimer level correlated significantly with clinical and pathological responses to chemotherapy. Pretherapeutic plasma d-dimer level can be used as a predictor for chemosensitivity.

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)

5th Monday, 2015  |   Uncategorized  |  no comments

Guibitang, a traditional herbal medicine, induces apoptotic death in A431 cells by regulating the activities of mitogen-activated protein kinases

1472-6882-14-344-2

Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are commonly referred to as non-melanoma skin cancers [1,2]. BCC is a slow-growing cancer that does not usually metastasize. Similarly, SCC is frequently localized without evidence of blood-born metastasis, making direct treatment of the tumor straightforward. However, SCC is the sixth most common cancer worldwide, and its incidence has increased dramatically at multiple sites in the body, including the head and neck, cervix, and lung [3,4]. Accordingly, it is necessary to develop novel effective chemopreventive agents to inhibit the development of SCC.

Guibitang (GBT), known as ‘Kihi-to’ in Japan and ‘Gui-Pi-Tang’ in China, is a traditional medicine and herbal formula that has been used for several hundred years, predominantly to treat insomnia, amnesia, palpitations, anxiety, fatigue, poor appetite, and depression [5]. Recent studies have reported the specific bioactivities of GBT, which include immune regulation [6], antioxidant effects [7], and protective effect of the gastric mucosa [8].

GBT is an aqueous polyherbal formulation that contains 12 herbs: Angelica gigas Nakai, Dimocarpus longan, Zizyphus jujuba Miller (seed), Polygala tenuifolia, Panax ginseng, Astragalus membranaceus, Atractylodes ovate, Poria cocos, Inula helenium, Glycyrrhiza glabra, Zingiber officinale, and Zizyphus jujuba Miller (Fructus). GBT also regulates chronic fatigue syndrome-associated cytokine production, whereas the addition of Gardenia jasminoides, Paeonia suffruticosa, and Bupleurum falcatum to GBT improves palliative care in patients undergoing chemotherapy for ovarian cancer [9]. Although it has been shown that adding several herbs to GBT results in anti-cancer effects against gynecological or lung cancer, the molecular mechanisms behind these effect of GBT remain unclear.

Tumorigenesis is caused by unregulated growth of cells resulting from DNA damage, mutations of functional genes, dysregulation of the cell cycle, and loss of apoptotic function [10]. Therefore, regulating the induction of apoptosis by modulating cell growth and survival-related signaling pathways is a common and major target for cancer therapies [11]. Among several signaling pathways in cancer cells, mitogen-activated protein kinase (MAPK) signals including extracellular signal-regulated kinases (ERK), p38 kinases, and c-Jun N-terminal kinases (JNK), take an important role in cell death and survival [12]. The regulation of ERK activation is induced by conditions of stress such as some agents and oxidant injury, which plays a major role in regulating cell growth and differentiation [13]. JNK and p38 are activated in response to several stress signals including tumor necrosis factor and hyperosmotic condition, which is associated with induction of apoptosis [14].

GBT showed cytotoxic activity against three different squamous cell carcinoma, especially on A431 cells. GBT induced the apoptosis through activating the caspase-8 in A431 cells. Inhibition of A431 cell growth by GBT was caused by G1-phase arrest through regulating proteins associated with cell cycle progression, such as cyclin D1, p21, and p27. Furthermore, GBT regulated the activation of mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK), p38 and c-Jun NH2-terminal kinase (JNK), and activated p53, a tumor suppressor protein. In MAPKs inhibitor study, inhibitors respectively blocked GBT-induced cell viability, indicating that MAPKs signals play critical role in cell death caused by GBT. In vivo xenografts, daily oral administration of 600 mg/kg GBT efficiently suppressed the tumorigenic growth of A431 cells without side effects such as loss of body weight and change of toxicological parameters compared to vehicle.

In the present study, Yim et al., (2014) evaluated whether GBT shows the anti-cancer effect in A431 human squamous carcinoma cells, which demonstrated that GBT induces apoptosis of cancer cells specifically, as an inhibition of the cell growth via regulating MAPK signaling pathway in A431 cells.

GBT decreases cell viability in A431 human squamous carcinoma cells
Six different human cancer cell lines (A431 [squamous], AGS [stomach], HeLa [cervical], Caki-1 [kidney], SK-Hep-1 [liver], and HCT116 [colon]) were treated with 500 ?g/mL GBT for 48 h, and cell viability was assessed by an MTT assay. Although most cell lines were unaffected, the viability of A431 cells was inhibited >35% by treatment with GBT (Figure 2A). Therefore, subsequent tests focused on A431 cells.

To further define the inhibitory action of GBT on SCCs, the suppression of cell growth by GBT on three different SCC lines (SCC12, SCC13, and A431) was evaluated. As shown in Figure 2B, treatment with 500 and 1000 ?g/mL GBT for 48 h reduced the viability of A431 cells by 35% and 52%, respectively. Treatment of SCC13 cells with 1000 ?g/mL GBT also inhibited the cell growth by ~30% although these effects were not as potent as those observed in A431 cells.

In contrast, the viability of SCC12 cells was not affected significantly by GBT. The potential cytotoxic effect of GBT on normal cells was assessed using normal human HaCaT keratinocytes and mouse primary liver cells. HaCaT cells were unaffected by GBT under the same conditions that were cytotoxic to A431 cells (Figure 2C). In addition, no cytotoxic effects on primary liver cells were observed by treatment with 500 ?g/mL or 1000 ?g/mL GBT. Instead, GBT weakly increased the viability of liver primary cells in a dose- and time-dependent manner. These results suggest that GBT has cancer-specific cytotoxic effect on A431 cells, without affecting normal cells.

Source
Yim N-H, Kim A, Liang C et al. BMC Complementary and Alternative Medicine 2014, 14:344 doi:10.1186/1472-6882-14-344

References
1. Diepgen TL, Mahler V: The epidemiology of skin cancer. Br J Dermatol 2002, 146(Suppl 61):1-6.
2. Weinstein MC, Brodell RT, Bordeaux J, Honda K: The art and science of surgical margins for the dermatopathologist. Am J Dermatopathol 2012, 34(7):737-745.
3. Sauter ER, Herlyn M, Liu SC, Litwin S, Ridge JA: Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin Cancer Res 2000, 6(2):654-660.
4. Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D: Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol 2007, 156(Suppl 3):1-7.
5. Tohda C, Ichimura M, Bai Y, Tanaka K, Zhu S, Komatsu K: Inhibitory effects of Eleutherococcus senticosus extracts on amyloid beta(25–35)-induced neuritic atrophy and synaptic loss. J Pharmacol Sci 2008, 107(3):329-339.
6. Busta I, Xei HS, Kim MS: The use of Gui-Pi-Tang in small animals with immune-mediated blood disorders. J Vet Clin 2009, 26:181-184.
7. Kang IH, Lee I, Han SH, Moon BS: Effects of Gwibitang on glutamate-induced apoptosis in C6 glial cells. J Korean Orient Med 2001, 22:45-57.
8. Kim HJ, Choi JH, Lim SW: The defensive effect of Keuibi-tang on the gastric mucous membrane of mouse injured by stress and ethanol. J Orient Med 2003, 24:155-168.
9. Ikeda A, Higashio S, Ushiroyama T: Experience with administration of kamikihito with chemotherapy and palliative care in patients with gynecologic cancer. Recent Prog Kampo Med Obstet Gynecol 2003, 20:152-155.
10. Kundoor V, Zhang X, Bommareddy A, Khalifa S, Fahmy H, Dwivedi C: Chemopreventive effects of sarcotriol on ultraviolet B-induced skin tumor development in SKH-1 hairless mice. Marine Drugs 2007, 5(4):197-207.
11. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H: Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68(2):339-342.
12. Hamamura K, Goldring MB, Yokota H: Involvement of p38 MAPK in regulation of MMP13 mRNA in chondrocytes in response to surviving stress to endoplasmic reticulum. Arch Oral Biol 2009, 54(3):279-286.
13. Fan M, Chambers TC: Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001, 5:253-267.
14. Dent P, Grant S: Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 2001, 7:775-783.

Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability

23rd Tuesday, 2014  |   Cancer  |  no comments

Untitled Source: Carcinogenesis (2009) 30 (7): 1073-1081. doi: 10.1093/carcin/bgp127 Inflammatory conditions in selected organs increase the risk of cancer. An inflammatory component is present also in the microenvironment of tumors that are not epidemiologically related to inflammation. Recent studies have begun to unravel molecular pathways linking inflammation and cancer. In the tumor microenvironment, smoldering inflammation contributes to proliferation and survival of malignant cells, angiogenesis, metastasis, subversion of adaptive immunity, reduced response to hormones and chemotherapeutic agents. Recent data suggest that an additional mechanism involved in cancer-related inflammation (CRI) is induction of genetic instability by inflammatory mediators, leading to accumulation of random genetic alterations in cancer cells. In a seminal contribution, Hanahan and Weinberg [(2000) Cell, 100, 57–70] identified the six hallmarks of cancer. We surmise that CRI represents the seventh hallmark. Introduction As early as in the 19th century it was perceived that cancer is linked to inflammation. This perception has waned for a long time. Recent years have seen a renaissance of the inflammation–cancer connection stemming from different lines of work and leading to a generally accepted paradigm (1–4). Epidemiological studies have revealed that chronic inflammation predisposes to different forms of cancer. Usage of non-steroidal anti-inflammatory agents is associated with protection against various tumors, a finding that to a large extent mirrors that of inflammation as a risk factor for certain cancers. The ‘inflammation–cancer’ connection is not restricted to increased risk for a subset of tumors. An inflammatory component is present in the microenvironment of most neoplastic tissues, including those not causally related to an obvious inflammatory process. Key features of cancer-related inflammation (CRI) include the infiltration of white blood cells, prominently tumor-associated macrophages (TAMs); the presence of polypeptide messengers of inflammation [cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, chemokines such as CCL2 and CXCL8] and the occurrence of tissue remodeling and angiogenesis. Recent efforts have shed new light on molecular and cellular circuits linking inflammation and cancer (4). Two pathways have been schematically identified; in the intrinsic pathway, genetic events causing neoplasia initiate the expression of inflammation-related programs that guide the construction of an inflammatory microenvironment [e.g. RET oncogene in papillary carcinoma of the thyroid (4–6)]. Oncogenes representative of different molecular classes and mode of action (tyrosine kinases, ras–raf, nuclear oncogenes and tumor suppressors) share the capacity to orchestrate proinflammatory circuits (e.g. angiogenetic switch; recruitment of myelo-monocytic cells). In the extrinsic pathway, inflammatory conditions facilitate cancer development. The triggers of chronic inflammation that increase cancer risk or progression include infections (e.g. Helicobacter pylori for gastric cancer and mucosal lymphoma; papilloma virus and hepatitis viruses for cervical and liver carcinoma, respectively), autoimmune diseases (e.g. inflammatory bowel disease for colon cancer) and inflammatory conditions of uncertain origin (e.g. prostatitis for prostate cancer). Key orchestrators at the intersection of the intrinsic and extrinsic pathway include transcription factors and primary proinflammatory cytokines (7,8). Thus, CRI is a key component of tumors and may represent the seventh hallmark of cancer (Figure 1) (6). Here, we will review molecular links connecting inflammation and cancer and their mutual influence. We will emphasize in particular emerging evidence suggesting that CRI may contribute to the genetic instability of cancer cells. Thus, CRI represents a target for innovative therapeutic strategies and prevention. These results provide further impetus for studies targeted to the inflammatory microenvironment of tumors [e.g. (10,11)]. Fig. 1. Above Inflammation as the seventh hallmark of cancer. An integration to the six hallmarks of cancer [modified from Hanahan and Weinberg (9) and Mantovani (6)]. Masters and commanders in CRI Transcription factors and primary inflammatory cytokines In the panoply of molecular players involved in CRI, one can identify prime movers (endogenous promoters). These include transcription factors such as nuclear factor-kappaB (NF-?B) and signal transducer activator of transcription-3 (Stat3) and primary inflammatory cytokines, such as IL-1?, IL-6 and TNF-? (12–15). NF-?B is a key orchestrator of innate immunity/inflammation and aberrant NF-?B regulation has been observed in many cancers (12). In both tumor and inflammatory cells, NF-?B is activated downstream of the toll-like receptor (TLR)-MyD88 pathway (sensing microbes and tissue damage) and of the inflammatory cytokines TNF-? and IL-1?. In addition, NF-?B activation can be the result of cell-autonomous genetic alterations (amplification, mutations or deletions) in cancer cells. Interestingly, NF-?B can be activated in response to hypoxia, though to a lesser extent than hypoxia inducible factor (HIF)-1? (7,16,17). Accumulating evidence suggests that intersections and compensatory pathways may exist between the NF-?B and HIF-1? systems linking innate immunity to the hypoxic response. NF-?B induces the expression of inflammatory cytokines, adhesion molecules, key enzymes in the prostaglandin synthase pathway (COX-2), nitric oxide (NO) synthase and angiogenic factors. In addition, by inducing antiapoptotic genes (e.g. Bcl2), it promotes survival in tumor cells and in epithelial cells targeted by carcinogens. A number of studies provided unequivocal evidence that NF-?B is involved in tumor initiation and progression in tissues in which CRI typically occurs (such as the gastrointestinal tract and the liver) (12,18,19). NF-?B gene targeting in epithelial cells can have divergent effects in different models of carcinogenesis, possibly depending on the balance between promotion of apoptosis in initiated cell and triggering of compensatory cell proliferation (18–20). Specific inactivation of NF-?B in tumor-infiltrating leukocytes, by a strategy targeting IkappaB-kinase beta, inhibited colitis-associated cancer, thus providing unequivocal genetic evidence for the role of NF-?B and inflammatory cells in intestinal carcinogenesis (18). The NF-?B pathway is tightly controlled by inhibitors acting at different levels. There is now evidence that Tir8 (also known as SIGIRR), an orphan member of the IL-1R family highly expressed in intestinal mucosa, inhibits signaling from the IL-1R/TLR complexes, possibly by trapping IRAK-1 and TRAF-6. In a mouse model of intestinal carcinogenesis in response to dextran sulfate sodium salt and azoxymethane administration, Tir8-deficient mice exhibited a dramatic susceptibility to inflammation and showed increased colon carcinogenesis, associated to local production of prostaglandin E2, proinflammatory cytokines (IL-1, IL-6) and chemokines (KC/CXC, JE/CCL2 and CCL3) (21,22). These mediators are downstream of NF-kB and have been shown to promote inflammation-propelled neoplasia (12). Thus, the lack of a checkpoint (Tir8) of NF-kB activation leads to increased carcinogenesis in the gastrointestinal tract, underlying once more the connection between chronic inflammation and cancer promotion. In addition, Tir8 gene deficiency is associated with B cell lymphoproliferation and autoimmunity (23). Along with NF-?B, STAT3 is a point of convergence for numerous oncogenic signaling pathways (13). Lee et al. (24) recently showed that the maintenance of NF-?B activation in tumors requires STAT3. This transcription factor is constitutively activated both in tumors and in immune cells and plays a role in carcinogenesis, as well as in tumor immune evasion by hampering dendritic cells maturation (13,25). Studies on colon cancer revealed that STAT3 is a major controller of cell proliferation and survival, regulating the expression of c-Myc, Mcl-1, Cyclin D and Bcl-2 (26). In lung adenocarcinomas, constitutive STAT3 phosphorylation is downstream of activating mutations in epidermal growth factor receptor (27,28). A major effector molecule of NF-kB activation and also linked to STAT3 is IL-6, a multi-functional cytokine with growth-promoting and antiapoptotic activity (29,30). Recent reports have provided evidence for the key role of the NF-kB–IL-6–STAT3 cascade. It was found that IL-6 produced by myeloid cells is a critical tumor promoter during intestinal carcinogenesis. IL-6 protects normal and premalignant intestinal epithelial cells from apoptosis and promotes the proliferation of tumor-initiating cells (31,32). Interestingly, STAT3 also regulates the balance between IL-12 and IL-23 in the tumor microenvironment and consequently the polarization of T-helper subsets (33). In multiple myeloma, a well-known IL-6-dependent neoplasia, it was described an alternative pathway of connection between IL-6 and NF-kB (34,35). Another link between IL-6 and cancer is in liver carcinogenesis. Naugler et al. have clarified the mechanisms underlying the increased susceptibility of male mice to hepatocellular carcinoma. Carcinogen-induced tissue injury activated, in liver macrophages of male mice, high levels of IL-6 in a TLR/MyD88-dependent manner. IL-6 promotes liver inflammation, injury, compensatory cell proliferation and carcinogenesis. In females, estrogen steroid hormones inhibit IL-6 production and so protect female mice from cancer (36,37). Among proinflammatory cytokines, TNF plays a major role. Originally identified as a cytokine inducing hemorrhagic necrosis of tumors, TNF soon turned out to have also protumoral functions. The finding that TNF-deficient mice are protected from skin carcinogenesis offered genetic evidence linking TNF-mediated inflammation and cancer (8,38). Tumor promotion by this cytokine can involve different pathways: TNF enhances tumor growth and invasion, leukocyte recruitment, angiogenesis and facilitate epithelial to mesenchymal transition (8,39,40). TNF secreted by TAM promotes Wnt/beta-catenin signaling through inhibition of glycogen synthase kinase 3 beta, which may contribute to tumor development in the gastric mucosa (41). In addition, TNF family members contribute to immune suppression; the decoy receptor-3 has been involved in the downregulation of major histocompatibility complex class II in TAM (42). On the whole, these findings provide a rationale for the development of clinical protocols employing TNF antagonists in cancer therapy. Phase I and II clinical cancer trials with TNF antagonists are under way and showed some clinical activity (11,43). Together with TNF and IL-6, also IL-1 has long been known to augment the capacity of cancer cells to metastatize, by affecting multiple steps of the CRI cascade (4,44,45). IL-1R1 gene-targeted mice have provided clear evidence for the protumor potential of IL-1 (14,46). In particular, in models of chemical carcinogen-induced tumors, IL-1? secreted by malignant cells or infiltrating leukocytes contributes to increased tumor adhesiveness and invasion, angiogenesis and immune suppression, whereas IL-1ra negatively controls these processes (47). In diethyl-nitrosamine-induced hepatocarcinoma, the unique membrane-associated form of IL-1? acts as protumorigenic mediator; diethyl-nitrosamine-induced hepatocyte death results in the release of IL-1? and activation of IL-1R signaling, leading to IL-6 induction and compensatory proliferation, critical for hepatocarcinogenesis (48). In a pancreatic islet tumor model, a first wave of myc-driven angiogenesis is induced by the inflammatory cytokine IL-1 (49). Polymorphisms of IL-1? are associated with an increased risk of gastric carcinoma (50). Stomach-specific expression of human IL-1? in transgenic mice lead to spontaneous gastric inflammation and cancer that correlated with early recruitment of myeloid-derived suppressor cells (MDSCs) (51). Recent studies have uncovered a novel relationship between sex steroid hormones, IL-1 and cancer. In carcinoma of the prostate, an androgen-dependent tumor sensitivity to hormonal stimulation is regulated by selective androgen receptor modulators. The inflammatory cytokine IL-1 produced by macrophages in the tumor microenvironment converts selective androgen receptor modulator from inhibitors to stimulators, thus inducing resistance to hormonal therapies (52). On the other hand, IL-1? is possibly of importance in 3-methylcholantrene-induced fibrosarcoma for its efficiency in activating antitumor innate and specific immune responses, by acting as a focused adjuvant, through binding to IL-1RI on cells deputed to immune surveillance (53,54). Moreover, small amounts of IL-1?, which is homeostatically expressed in cells but not secreted, can be poured out from necrotizing cells and serve as a ‘danger signal’ for mounting antitumor immunity (55). These findings call attention to the concept that inflammatory reactions can also trigger antitumor activity (4). Significance of myeloid cell recruitment within tumors Besides neoplastic cells, the ‘other half’ of the tumor is composed of a stroma containing fibroblasts, vessels and leukocytes. TAMs are the principal leukocyte subset driving an amplification of the inflammatory response in the tumor milieu. However, also mast cells, neutrophils and even effectors of the adaptive immunity (especially in the form of antibodies) may activate inflammatory reactions that promote cancer progression (56,57). Chemokines have long been associated with the recruitment of TAM in tumors (e.g. CCL2 and CCL5) (4,58). For their phenotypic and functional properties, TAM resembles M2-polarized macrophages, though there are some distinctive features (59,60). In most studies, accumulation of TAM has been associated with the angiogenic switch and poor prognosis (3,4,61,62). TAM assists tumor cell malignant behavior in many ways by releasing cytokines, growth factors and matrix-degrading enzymes (63–66) and a host of angiogenic factors (e.g. vascular endothelial growth factor (VEGF), platelet-derived growth factor, fibroblast growth factor and CXCL8) (1,67–77). It is well known that TAM accumulates in hypoxic regions of tumors and hypoxia triggers a proangiogenic program in these cells (67). Recent results suggest that TAM promotes tumor angiogenesis also via Semaphorin 4D (78). Monocytes express VEGF receptors and VEGF is a known chemoattractant of myeloid cells in tumors (79). VEGF1R+ hematopoietic cells home to tumor-specific premetastatic sites that favors secondary localization of cancer (80,81). Recently, new evidence was provided that a distinct subset of monocytes expressing the Tie2 receptor (TEM) has a major role in tumor angiogenesis (82–84). Conditional deletion of Tie2+ myeloid cells in mice resulted in significant reduction of transplanted tumor mass and vasculature, demonstrating the importance of TEM in neoangiogenesis (82). Like TAM, TEM are clustered in hypoxic areas of solid tumors, in close proximity to nascent tumor vessels. The tumor-homing ability of TEM has been suggested as a potential vehicle for antitumor gene delivery (e.g. IFN?) (85). Chemokines (e.g. CXCL5 and CXCL12) are also involved in the attraction of MDSCs (86,87). MDSCs, like TAM, are important effectors in tumor angiogenesis (88,89) and Gr+Mac1+ cells, presumably MDSC, have been shown to mediate resistance to antiangiogenic therapy (90). Tumor progression is largely mediated by the host inability to mount a protective antitumor immune response. TAM and MDSC express a large immunosuppressive repertoire. In addition to inhibit CD8 T cell activation by the expression of NOS2 and Arg1, MDSC induce the development of CD4+FOXP3+ T-regulatory cells and an M2 polarization of TAM (87,91–93). Indoleamine 2,3 dioxygenase is a key immunosuppressive factor. Skin application of phorbol myristate acetate provoked a chronic inflammation and release of indoleamine 2,3 dioxygenase that facilitated tumor progression (94). The immunoregulatory activity of TAM is mostly influenced by cues encountered locally in tissues. In the tumor milieu, a number of immunosuppressive factors (e.g. IL-10 and transforming growth factor-?) have been described to affect the differentiation of incoming monocytes toward M2 macrophages (59,62,64,95). NF-?B has also been recently involved in driving the M2 polarization of TAM (96). In established advanced tumors, where inflammation is typically smoldering (4), TAM have defective and delayed NF-?B activation (97) and substantial data suggest that p50 homodimers (acting as negative regulators of NF-?B) are responsible for the sluggish NF-?B activation in TAMs and for their protumor phenotype. Metabolic changes in the tumor milieu, in addition to provide growth and survival advantages for cancer cells, may also influence infiltrating leukocytes (98). It was found that lactic acid secreted by tumor cells promotes the IL-23/IL-17 axis in TAM (99). Thus, lactic acid is a proinflammatory stimulus inducing the IL-23/IL-17 pathway to the expenses of the immunoprotective IL-12-inducible Th1 pathway. Also, components of the extracellular matrix may constitute a link between tumor cells and macrophages. Kim et al. (100) have recently reported that versican, by triggering the innate receptors TLR2/TLR6 on TAM, amplifies an inflammatory cascade leading to enhanced metastasis. Previous SectionNext Section The perfect storm: CRI and tumor cell genetic instability In the extrinsic pathway, it remains uncertain whether chronic inflammation per sé is sufficient for carcinogenesis. Reactive oxygen and nitrogen intermediates are obvious inflammation-generated candidate mediators for DNA damage and evidence obtained in vitro and in vivo is consistent with this view (4). Hereafter, we summarize data suggesting that inflammatory cells and mediators can destabilize the cancer cell genome by a variety of mechanisms either directly inducing DNA damage or affecting DNA repair systems and altering cell cycle checkpoints (Figure 2). These emerging data suggest that an additional mechanism by which inflammation can contribute to cancer initiation and progression is genetic destabilization of cancer cells. Untitled1 Fig. 2. Molecular pathways linking CRI and genetic instability. Schematic representation of inflammation-related pathways leading to microsatellite and CI in cancer cells. Inflammatory cells produce reactive oxygen and nitrogen species (RONS) and other mediators, including cytokines, metalloproteinases (MMPs) and PGE2, which, in turn, amplify and perpetuate the inflammatory cascade (e.g. MMPs induce reactive oxygen intermediates, cytokines induce PGE2). Inflammatory mediators by a variety of mechanisms (see text) downregulate DNA repair pathways (e.g. MMR system) inducing MSI. Inflammatory mediators affect also CI by inducing either directly or indirectly DSB, defective mitotic checkpoints and disregulated HR pathway of DSB repair. The inflammatory cytokine TNF also upregulates the AID that, in addition to hypermutate Ig loci, can also induce point mutations and translocations (through DSB). MSI and CI induce random genetic diversification of expanding cancer cells. Cancer clones that randomly acquired the right combination of activated oncogenes and inactivated oncosuppressors will display the six hallmarks of cancer phenotype described by Weinberg and Hanahan. An unstable genome is a hallmark feature of nearly all solid tumors and adult-onset leukemias (101,102). Cancer genetic instability through accelerated somatic evolution leads to a genomically heterogenous population of expanding cells naturally selected for their ability to proliferate, invade distant tissues and evading host defenses (103). Genetic instability in cancer reflects an increased rate of DNA alterations in tumor cells, which may arise either from increased rates of damage or defective mechanisms that maintain genetic integrity within cells (101,102). Such systems recognize and correct damaged DNA, regulate the proper timing and accuracy of the genetic material duplication and faithfully segregate chromosomes into the daughter cells (104). Inflammation and microsatellite instability Mismatch repair (MMR) family members repair base–base mispairs and larger insertions/deletions (104). Mutations or epigenetic silencing of MMR members is associated with increased genetic instability termed as microsatellite instability (MSI), shown as increased rates of DNA replication errors throughout the genome. These errors preferentially affect genes such as TGF?RII, IGF-2R and BAX that contain in their coding regions microsatellites (short repetitive nucleotide sequences in DNA) that are intrinsically unstable and therefore prone to be copied incorrectly during DNA replication (101). Inflammation downregulates MMR proteins by a variety of mechanisms. HIF-1?, which is induced in cancer cells by inflammatory cytokines (TNF and IL-1?), PGE2 (105) and reactive oxygen and nitrogen species (106) downregulate MMR proteins MSH2 and MSH6 by displacing c-Myc from MSH2/MSH6 promoters (107). Hydrogen peroxide inactivates MMR members by damaging the enzymes at the protein level (108). Direct evidence for the role of oxidative stress in carcinogenesis via MMR inactivation comes from experiments that induce frameshift mutations in a reporter gene after exposure to hydrogen peroxide (109). NO-induced upregulation of DNA methyltransferase results in extensive methylation of the cytosine bases, which is associated with promoter silencing and loss of gene expression of the MMR member hMLH1 (110). By immunohistochemistry, decreased levels of hMLH1 proteins are seen in gastric epithelial cells in H.pylori-positive patients (111). In colitis-associated cancers, hMLH1 hypermethylation is observed in a substantial proportion of patients (110). MSI can be detected early in premalignant tissues without dysplasia of patients with ulcerative colitis (UC), suggesting that inactivation of the MMR system is an early event in colon carcinogenesis in UC (112,113). In an in vitro model, exposure to activated neutrophils, which accumulate within crypts in UC, increases the number of replication errors in colonic cells (114). While the MMR pathway has frequently been the focus of MSI studies, also the base excision repair (BER) pathway, which deals with base damage (104), may be implicated (115). In tissues from non-cancerous colons of UC patients, two BER enzymes (AAG and APE1) are significantly increased with a positive correlation with MSI (116). Mechanistic studies have shown that overexpression of these BER enzymes enhances MSI (116). This finding must be considered also in the view that reactive oxygen species (ROS) induce BER members (116,117) and that the BER enzyme APE1 promoter contains the consensus sequence for binding NF-kB (117). The nucleotide excision repair pathway, which serves to repair a variety of DNA lesions caused by UV radiation, mutagenic chemicals and chemotherapeutic agents (104), appears to be affected by IL-6 that in multiple myeloma cells induces hypermethylation, and thus defective function, of the key nucleotide excision repair component hHR23B (118). HIF-1? induces the microRNA-373 that downregulates the expression of the nucleotide excision repair component RAD23B (119). Inflammation and chromosomal instability Chromosomal instability (CI) results in abnormal segregation of chromosomes and aneuploidy (120). Molecular mechanisms underlying CI are only partially described. In most cancers with CI, proteins of the mitotic checkpoints are disregulated (120). As a consequence, cancer cells fail to halt the cell cycle until DNA repair can be executed. Recently, a CI signature associated with cancer has been described in which 29 of 70 genes included in the signature are mitotic regulators (121). Inactivation of p53 may play a role in CI (122). The p53 pathway protects cells from transformation by inducing apoptosis upon DNA damage and CI. p53 deficiency and a defective mitotic checkpoint in T lymphocytes increase CI through aberrant exit from mitotic arrest (123). Loss of p53 and p73 are associated with increased aneuploidy in mouse embryonic fibroblasts (124). The proinflammatory cytokine migration inhibitory factor suppresses p53 activity as a transcriptional activator (125). NO and its derivatives inhibit the function of p53 (126,127) and are associated with p53 mutations (113,128–131). NO (132) and the inflammatory cytokine IL-6 (118) increase the activity of DNA methyltransferase, resulting in CpG island methylation. Most of the p53 mutations in UC-associated cancers are G:C to A:T transitions at two hot spot CpG dinucleotide sites (113,133). In UC, p53 mutations occur early and are often detected in mucosa that is non-dysplastic (134,135). The DNA/RNA editing enzyme activation-induced cytidine deaminase (AID) induces hypermutation of the immunoglobulin loci in B cells. AID is overexpressed in human lymphoid malignancies (136,137) and, ectopically, in cholangiosarcoma biopsies (8,137), gastric epithelial cells of H.pylori-positive chronic gastritis and cancer (138), inflamed colonic mucosa of UC and in colitis-associated cancer (139), in human hepatocellular carcinoma and surrounding non-cancerous liver tissue with underlying chronic inflammation (140) and in human liver with chronic hepatic inflammation caused by hepatitis C virus infection (140). AID is induced by the inflammatory cytokines TNF and IL-1? (139,141), by the T-helper cell 2-driven cytokines IL-4 and IL-13 (142) and by transforming growth factor-? (140). In addition to targeting immunoglobulin loci in B cells, AID produces mutations and translocations [through induction of double-strand breaks (DSBs), see below] in a number of other genes, including p53, c-Myc and BCL6 (143–145). Apart from its peroxidase activity that would increase oxidative stress in cells, COX-2 overexpression in breast cancer cells was associated with a significant increase in chromosomal aberrations (fusions, breaks and tetraploidy), possibly due to COX-2-mediated activation of AKT-induced inhibitory phosphorylation of CHK1 (146), whose haploinsufficiency induces accumulation of DNA damage by failure to restrain mitotic entry in the presence of a damaged S-phase (147). Malignant cells employ matrix metalloproteinases (MMPs) to penetrate the extracellular matrix and basement membrane and to invade distant tissues. Recent data suggest that MMPs may also function as oncogenes by promoting CI. MT1-MMP, which is present also in the pericentrosomal compartment, compromises normal cytokinesis inducing aneuploidy. Overexpression of MT1-MMP caused increased chromosome numbers and multipoles along with misaligned mitotic spindle formation (148). A potential target of MT1-MMP is pericentrin, an integral centrosomal/midbody protein required for centrosome performance and chromosome segregation (149). Endogenous pericentrin is cleaved in different cell types transfected with MT1-MMP (149). MMP-3, which is upregulated in many breast cancers (150), also mediates CI in cultured cells and in transgenic mice (151,152). Expression of MMP-3 in cells stimulates the production of Rac1b (153), an hyperactive alternative splicing form of Rac1, which stimulates ROS production which can cause oxidative DNA damage and CI (154). The retinoblastoma protein is hyperphosphorylated in both mouse and human colitis (155). NO induces hyperphosphorylation of retinoblastoma protein (156). In its hyperphosphorylated form, retinoblastoma protein releases the E2 promoter-binding factor-1 (E2F1) (155), leading to CI by upregulation of Mad2 that is overexpressed in several tumor types (157). Elevated Mad2, a key component of the spindle checkpoint, can produce a hyperactive spindle checkpoint and thereby altering the sequence of mitotic events and the accuracy of chromosome segregation (157). Mad2 is also involved in FAT10-induced CI. FAT10, a member of the ubiquitin-like modifier family of proteins, is overexpressed in 90% of hepatocellular carcinoma and in >80% of colon, ovary and uterus carcinomas (158). FAT10 impairs Mad2 during mitosis, inducing an abbreviated mitotic phase and CI (159). IFN-? and TNF-? synergistically upregulate FAT10 expression in liver and colon cancer cells 10- to 100-fold (160). FAT10 expression in malignancies is also attributed to transcriptional upregulation upon the loss of p53 (161). Several agents induce DSBs in cancer cells, including reactive oxygen and nitrogen species (162,163), irradiation and chemotherapeutic agents. Moreover, ROS induce DSB increasing (163) by increasing telomere erosion due to loss of recognition of these sites by telomere protective proteins such as telomere repeat binding factors 1 and 2 (164,165). There are two major mechanisms for DSB repair, homologous recombination (HR) (166) and non-homologous end joining (167). Induction of DSB impairs genome integrity since the non-homologous end-joining pathway is intrinsically error prone, resulting in small regions of non-template nucleotides around the DNA break. Moreover, a very precise regulation of the error-free HR mechanisms is also essential for genome stability since uncontrolled HR excess promotes CI as well as HR deficiency. Growth factors and chemokines produced by inflammatory cells in tumor microenvironment induce overexpression of structurally normal c-Myc in cancer cells. c-Myc alters the expression of hundreds of target genes related to cell growth, apoptosis and invasion. However, c-Myc also accelerates the intrinsic mutation rate in cancer cells. c-Myc induces DSB, as well as activated Ras (168), by production of ROS (169) (see above) and utilization of cryptic replication origins leading to aberrant and incomplete DNA synthesis (170). In addition, c-Myc drives aberrant DNA synthesis as a result of upregulation of cyclin B1, particularly when coupled with p53 deficiency (171). Finally, c-Myc delays prometaphase inducing chromosomal missegregation by direct transactivation of the spindle checkpoint proteins Mad2 and BubR1 (172) and mitigates p53 function (169). Inflammatory mediators affect the expression and activity of DSB repair mechanisms. Bcl-2 is overexpressed in cancer cells by a variety of stimuli from the tumor microenvironment through NF-kB activation (12). The oncogenic role of Bcl-2 might extend well beyond the inhibition of apoptotic death. Bcl-2 inhibits DSB repair resulting in elevated frequencies of inducible and spontaneous mutagenesis by posttranslational modification (173) and inhibition the HR member RAD51 (104). Several cytokines and growth factors activate the signal transducer JAK-2. Mutated JAK-2 and, to a lesser extent, wild-type JAK-2 increase the HR pathway inducing CI (174). HIF-1?, which is upregulated by inflammatory cytokines, induces miR-210 and miR-373 that in turn downregulate expression of the HR member RAD52 (119). Is inflammation associated with genetic instability in non-cancer conditions? The concept that an inflammatory microenvironment contributes to genome destabilization in cancer is in keeping with findings of MSI and CI also in non-cancer-related inflammatory conditions. The mutation rate in the inflamed microenvironment is higher than in normal tissues, with a mutation frequency of 4?×?10?8 and Concluding remarks Inflammation is a key component of the tumor microenvironment. Recent efforts have shed new light on molecular and cellular pathways linking inflammation and cancer (4). Schematically, two pathways have emerged; in the intrinsic one, activation of different classes of oncogenes drives the expression of inflammation-related programs that guide the construction of an inflammatory milieu. In the extrinsic pathway, inflammatory conditions promote cancer development. Key orchestrators of the inflammation-mediated tumor progression (the dark side of the force) are transcription factors, cytokines, chemokines and infiltrating leukocytes. The high degree of genetic heterogeneity in tumors suggests that genetic instability is an ongoing process throughout tumor development. Accumulating evidence supports the view that inflammatory mediators, some of that are direct mutagens, also directly or indirectly downregulate DNA repair pathways and cell cycle checkpoints, thus destabilizing cancer cell genome and contributing to the accumulation of random genetic alterations. These in turn accelerate the somatic evolution of cancer to a genomically heterogenous population of expanding cells naturally selected for their ability to proliferate, invade and evade host defenses (103). CRI represents a target for innovative therapeutic strategies. For many years, all efforts to treat cancer have concentrated on the destruction/inhibition of tumor cells. Strategies to modulate the host microenvironment offer a complementary perspective. Primary proinflammatory cytokines represent prime targets and ongoing results in this direction justify continuing efforts (10,11). Finally, inflammatory reactions can also result in antitumor activity (the bright side of the force) (4,95,182). This dual function of inflammatory cells and mediators is reflected by studies on correlations between parameters of CRI and clinical behavior in different contexts (183–188). The challenge now is to identify the mechanisms triggering a ‘bright’ inflammatory response leading to tumor inhibition, whereas neutralizing the protumor actions of the dark side (4). References 1. Balkwill F, et al. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. CrossRefMedlineWeb of ScienceGoogle Scholar 2. Coussens LM, et al. Inflammation and cancer. Nature 2002;420:860-867. CrossRefMedlineWeb of ScienceGoogle Scholar 3. Balkwill F, et al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217. CrossRefMedlineWeb of ScienceGoogle Scholar 4. Mantovani A, et al. Cancer-related inflammation. Nature 2008;454:436-444. CrossRefMedlineWeb of ScienceGoogle Scholar 5. Borrello MG, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl Acad. Sci. USA 2005;102:14825-14830. Abstract/FREE Full Text 6. Mantovani A. Cancer: inflaming metastasis. Nature 2009;457:36-37. CrossRefMedlineWeb of ScienceGoogle Scholar 7. Rius J, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008;453:807-811. CrossRefMedlineWeb of ScienceGoogle Scholar 8. Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009;9:361-371. CrossRefMedlineWeb of ScienceGoogle Scholar 9. Hanahan D, et al. The hallmarks of cancer. Cell 2000;100:57-70. CrossRefMedlineWeb of ScienceGoogle Scholar 10. Loberg RD, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67:9417-9424. Abstract/FREE Full Text 11. Harrison ML, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 2007;25:4542-4549. Abstract/FREE Full Text 12. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436. CrossRefMedlineWeb of ScienceGoogle Scholar 13. Yu H, et al. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007;7:41-51. CrossRefMedlineWeb of ScienceGoogle Scholar 14. Voronov E, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 2003;100:2645-2650. Abstract/FREE Full Text 15. Langowski JL, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-465. CrossRefMedlineWeb of ScienceGoogle Scholar 16. Carbia-Nagashima A, et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 2007;131:309-323. CrossRefMedlineWeb of ScienceGoogle Scholar 17. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J. Physiol. 2008;586:4055-4059. Abstract/FREE Full Text 18. Greten FR, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296. CrossRefMedlineWeb of ScienceGoogle Scholar 19. Pikarsky E, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466. CrossRefMedlineWeb of ScienceGoogle Scholar 20. Maeda S, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005;121:977-990. CrossRefMedlineWeb of ScienceGoogle Scholar 21. Garlanda C, et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory members of the IL-1 receptor family. Cancer Res. 2007;67:6017-6021. Abstract/FREE Full Text 22. Xiao H, et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007;26:461-475. CrossRefMedlineWeb of ScienceGoogle Scholar 23. Lech M, et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J. Exp. Med. 2008;205:1879-1888. Abstract/FREE Full Text 24. Lee H, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283-293. CrossRefMedlineWeb of ScienceGoogle Scholar 25. Kortylewski M, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005;11:1314-1321. CrossRefMedlineWeb of ScienceGoogle Scholar 26. Becker C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501. CrossRefMedlineWeb of ScienceGoogle Scholar 27. Gao SP, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 2007;117:3846-3856. CrossRefMedlineWeb of ScienceGoogle Scholar 28. Grivennikov S, et al. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008;13:7-9. CrossRefMedlineWeb of ScienceGoogle Scholar 29. Lin WW, et al. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007;117:1175-1183. CrossRefMedlineWeb of ScienceGoogle Scholar 30. Naugler WE, et al. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008;14:109-119. CrossRefMedlineWeb of ScienceGoogle Scholar 31. Grivennikov S, et al. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-113. CrossRefMedlineWeb of ScienceGoogle Scholar 32. Bollrath J, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102. CrossRefMedlineWeb of ScienceGoogle Scholar 33. Kortylewski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009;15:114-123. CrossRefMedlineWeb of ScienceGoogle Scholar 34. Annunziata CM, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-130. CrossRefMedlineWeb of ScienceGoogle Scholar 35. Keats JJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-144. CrossRefMedlineWeb of ScienceGoogle Scholar 36. Naugler WE, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent-IL-6 production. Science 2007;317:121-124. Abstract/FREE Full Text 37. Rakoff-Nahoum S, et al. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007;317:124-127. Abstract/FREE Full Text 38. Moore RJ, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999;5:828-831. CrossRefMedlineWeb of ScienceGoogle Scholar 39. Popivanova BK, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008;118:560-570. MedlineWeb of ScienceGoogle Scholar 40. Kulbe H, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007;67:585-592. Abstract/FREE Full Text 41. Oguma K, et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008;27:1671-1681. CrossRefMedlineWeb of ScienceGoogle Scholar 42. Chang YC, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 2008;111:5054-5063. Abstract/FREE Full Text 43. Brown ER, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann. Oncol. 2008;19:1340-1346. Abstract/FREE Full Text 44. Giavazzi R, et al. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res. 1990;50:4771-4775. Abstract/FREE Full Text 45. Luo JL, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007;446:690-694. CrossRefMedlineWeb of ScienceGoogle Scholar 46. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307-313. CrossRefMedlineWeb of ScienceGoogle Scholar 47. Krelin Y, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67:1062-1071. Abstract/FREE Full Text 48. Sakurai T, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008;14:156-165. CrossRefMedlineWeb of ScienceGoogle Scholar 49. Shchors K, et al. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 2006;20:2527-2538. Abstract/FREE Full Text 50. El-Omar EM, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402. CrossRefMedlineWeb of ScienceGoogle Scholar 51. Tu S, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008;14:408-419. CrossRefMedlineWeb of ScienceGoogle Scholar 52. Zhu P, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615-629. CrossRefMedlineWeb of ScienceGoogle Scholar 53. Marhaba R, et al. Opposing effects of fibrosarcoma cell-derived IL-1 alpha and IL-1 beta on immune response induction. Int. J. Cancer 2008;123:134-145. CrossRefMedlineWeb of ScienceGoogle Scholar 54. Elkabets M, et al. Host-derived interleukin-1? is important in determining the immunogenicity of 3-methylcholantrene-tumor cells. J. immunol. 2009;182:4874-4881. Abstract/FREE Full Text 55. Chen CJ, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 2007;13:851-856. CrossRefMedlineWeb of ScienceGoogle Scholar 56. de Visser KE, et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006;6:24-37. CrossRefMedlineWeb of ScienceGoogle Scholar 57. Galli SJ, et al. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 2008;8:478-486. CrossRefMedlineWeb of ScienceGoogle Scholar 58. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004;4:540-550. CrossRefMedlineWeb of ScienceGoogle Scholar 59. Mantovani A, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555. CrossRefMedlineWeb of ScienceGoogle Scholar 60. Sica A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006;42:717-727. CrossRefMedlineWeb of ScienceGoogle Scholar 61. Bingle L, et al. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002;196:254-265. CrossRefMedlineWeb of ScienceGoogle Scholar 62. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004;4:71-78. CrossRefMedlineWeb of ScienceGoogle Scholar 63. Wyckoff JB, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649-2656. Abstract/FREE Full Text 64. Mantovani A, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315-322. CrossRefMedlineWeb of ScienceGoogle Scholar 65. Condeelis J, et al. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266. CrossRefMedlineWeb of ScienceGoogle Scholar 66. Yang L, et al. Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008;13:23-35. CrossRefMedlineWeb of ScienceGoogle Scholar 67. Murdoch C, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008;8:618-631. CrossRefMedlineWeb of ScienceGoogle Scholar 68. Du R, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-220. CrossRefMedlineWeb of ScienceGoogle Scholar 69. Seandel M, et al. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. Cancer Cell 2008;13:181-183. CrossRefMedlineWeb of ScienceGoogle Scholar 70. Ahn GO, et al. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008;13:193-205. CrossRefMedlineWeb of ScienceGoogle Scholar 71. Dineen SP, et al. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008;68:4340-4346. Abstract/FREE Full Text 72. Kusmartsev S, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 2008;181:346-353. Abstract/FREE Full Text 73. Duluc D, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007;110:4319-4330. Abstract/FREE Full Text 74. Morandi F, et al. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007;67:6433-6441. Abstract/FREE Full Text 75. Robinson-Smith TM, et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67:5708-5716. Abstract/FREE Full Text 76. Stearman RS, et al. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res. 2008;68:34-43. Abstract/FREE Full Text 77. Lewis CE, et al. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612. Abstract/FREE Full Text 78. Sierra JR, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J. Exp. Med. 2008;205:1673-1685. Abstract/FREE Full Text 79. Fischer C, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-475. CrossRefMedlineWeb of ScienceGoogle Scholar 80. Kaplan RN, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-827. CrossRefMedlineWeb of ScienceGoogle Scholar 81. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv. Cancer Res. 2008;100:203-229. CrossRefMedlineWeb of ScienceGoogle Scholar 82. De Palma M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-226. CrossRefMedlineWeb of ScienceGoogle Scholar 83. De Palma M, et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 2003;9:789-795. CrossRefMedlineWeb of ScienceGoogle Scholar 84. De Palma M, et al. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends. Immunol. 2007;28:519-524. CrossRefMedlineWeb of ScienceGoogle Scholar 85. De Palma M, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008;14:299-311. CrossRefMedlineWeb of ScienceGoogle Scholar 86. Sawanobori Y, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008;111:5457-5466. Abstract/FREE Full Text 87. Sica A, et al. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007;117:1155-1166. CrossRefMedlineWeb of ScienceGoogle Scholar 88. Yang L, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-421. CrossRefMedlineWeb of ScienceGoogle Scholar 89. Noonan DM, et al. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev. 2008;27:31-40. CrossRefMedlineWeb of ScienceGoogle Scholar 90. Shojaei F, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007;25:911-920. CrossRefMedlineWeb of ScienceGoogle Scholar 91. Huang B, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123-1131. Abstract/FREE Full Text 92. Sinha P, et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007;179:977-983. Abstract/FREE Full Text 93. Nagaraj S, et al. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008;68:2561-2563. Abstract/FREE Full Text 94. Muller AJ, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl Acad. Sci. USA 2008;105:17073-17078. Abstract/FREE Full Text 95. Allavena P, et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008;222:155-161. CrossRefMedlineWeb of ScienceGoogle Scholar 96. Hagemann T, et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008;205:1261-1268. Abstract/FREE Full Text 97. Biswas SK, et al. A distinct and unique transcriptional programme expressed by tumor-associated macrophages: defective NF-kB and enhanced IRF-3/STAT1 activation. Blood 2006;107:2112-2122. Abstract/FREE Full Text 98. Tennant DA, et al. Metabolic transformation in cancer. Carcinogenesis 2009. in press. Google Scholar 99. Shime H, et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol. 2008;180:7175-7183. Abstract/FREE Full Text 100. Kim S, et al. Carcinoma produced factors activate myeloid cells via TLR2 to stimulate metastasis. Nature 2009;457:102-106. CrossRefMedlineWeb of ScienceGoogle Scholar 101. Loeb LA, et al. DNA polymerases and human disease. Nat. Rev. Genet. 2008;9:594-604. CrossRefMedlineWeb of ScienceGoogle Scholar 102. Rajagopalan H, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934. CrossRefMedlineWeb of ScienceGoogle Scholar 103. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8. Abstract/FREE Full Text 104. Hakem R. DNA-damage repair; the good, the bad, and the ugly. EMBO J. 2008;27:589-605. CrossRefMedlineWeb of ScienceGoogle Scholar 105. Jung YJ, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17:2115-2117. Abstract/FREE Full Text 106. Sandau KB, et al. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem. Biophys. Res. Commun. 2000;278:263-267. CrossRefMedlineWeb of ScienceGoogle Scholar 107. Koshiji M, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 2005;17:793-803. CrossRefMedlineWeb of ScienceGoogle Scholar 108. Chang CL, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell Physiol. 2002;283:C148-C154. Abstract/FREE Full Text 109. Gasche C, et al. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res. 2001;61:7444-7448. Abstract/FREE Full Text 110. Fleisher AS, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000;60:4864-4868. Abstract/FREE Full Text 111. Mirzaee V, et al. Helicobacter pylori infection and expression of DNA mismatch repair proteins. World J. Gastroenterol. 2008;14:6717-6721. CrossRefMedlineWeb of ScienceGoogle Scholar 112. Brentnall TA, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 1996;56:1237-1240. Abstract/FREE Full Text 113. Hussain SP, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60:3333-3337. Abstract/FREE Full Text 114. Campregher C, et al. Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells. Gut 2008;57:780-787. Abstract/FREE Full Text 115. Guo HH, et al. Tumbling down a different pathway to genetic instability. J. Clin. Invest. 2003;112:1793-1795. CrossRefMedlineWeb of ScienceGoogle Scholar 116. Hofseth LJ, et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 2003;112:1887-1894. CrossRefMedlineWeb of ScienceGoogle Scholar 117. Ramana CV, et al. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc. Natl Acad. Sci. USA 1998;95:5061-5066. Abstract/FREE Full Text 118. Hodge DR, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005;65:4673-4682. Abstract/FREE Full Text 119. Crosby ME, et al. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009;69:1221-1229. Abstract/FREE Full Text 120. Rajagopalan H, et al. The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 2003;3:695-701. CrossRefMedlineWeb of ScienceGoogle Scholar 121. Roschke AV, et al. Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance. Neoplasia 2008;10:1222-1230. MedlineWeb of ScienceGoogle Scholar 122. Tomasini R, et al. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008;18:244-252. CrossRefMedlineWeb of ScienceGoogle Scholar 123. Baek KH, et al. p53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. J. Leukoc. Biol. 2003;73:850-861. Abstract/FREE Full Text 124. Talos F, et al. p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol. Cell 2007;27:647-659. CrossRefMedlineWeb of ScienceGoogle Scholar 125. Hudson JD, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 1999;190:1375-1382. Abstract/FREE Full Text 126. Calmels S, et al. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 1997;57:3365-3369. Abstract/FREE Full Text 127. Cobbs CS, et al. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res. 2003;63:8670-8673. Abstract/FREE Full Text 128. Ambs S, et al. Cancer-prone oxyradical overload disease. IARC Sci. Publ. 1999;150:295-302. MedlineGoogle Scholar 129. Marshall HE, et al. Nitrosation and oxidation in the regulation of gene expression. FASEB J. 2000;14:1889-1900. Abstract/FREE Full Text 130. Jaiswal M, et al. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001;281:G626-G34. Abstract/FREE Full Text 131. Wink DA, et al. The Fpg protein, a DNA repair enzyme, is inhibited by the biomediator nitric oxide in vitro and in vivo. Carcinogenesis 1994;15:2125-2129. Abstract/FREE Full Text 132. Hmadcha A, et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J. Exp. Med. 1999;190:1595-1604. Abstract/FREE Full Text 133. Goodman JE, et al. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ. Mol. Mutagen. 2004;44:3-9. CrossRefMedlineWeb of ScienceGoogle Scholar 134. Brentnall TA, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-378. MedlineWeb of ScienceGoogle Scholar 135. Burmer GC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992;103:1602-1610. MedlineWeb of ScienceGoogle Scholar 136. Greeve J, et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003;101:3574-3580. Abstract/FREE Full Text 137. Lossos IS, et al. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. Leukemia 2004;18:1775-1779. CrossRefMedlineWeb of ScienceGoogle Scholar 138. Matsumoto Y, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 2007;13:470-476. CrossRefMedlineWeb of ScienceGoogle Scholar 139. Endo Y, et al. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 2007;26:5587-5595. CrossRefMedlineWeb of ScienceGoogle Scholar 140. Kou T, et al. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int. J. Cancer 2007;120:469-476. CrossRefMedlineWeb of ScienceGoogle Scholar 141. Komori J, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008;47:888-896. CrossRefMedlineWeb of ScienceGoogle Scholar 142. Endo Y, et al. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 2008;135:889-898. 898, e1–e3. CrossRefMedlineWeb of ScienceGoogle Scholar 143. Chesi M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13:167-180. CrossRefMedlineWeb of ScienceGoogle Scholar 144. Robbiani DF, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008;135:1028-1038. CrossRefMedlineWeb of ScienceGoogle Scholar 145. Shen HM, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998;280:1750-1752. Abstract/FREE Full Text 146. Singh B, et al. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J. Surg. Res. 2007;140:220-226. CrossRefMedlineWeb of ScienceGoogle Scholar 147. Lam MH, et al. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004;6:45-59. CrossRefMedlineWeb of ScienceGoogle Scholar 148. Golubkov VS, et al. Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J. Biol. Chem. 2005;280:25079-25086. Abstract/FREE Full Text 149. Golubkov VS, et al. Proteolysis-driven oncogenesis. Cell Cycle 2007;6:147-150. MedlineWeb of ScienceGoogle Scholar 150. Sternlicht MD, et al. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001;17:463-516. CrossRefMedlineWeb of ScienceGoogle Scholar 151. Sternlicht MD, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-146. CrossRefMedlineWeb of ScienceGoogle Scholar 152. Lochter A, et al. Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J. Biol. Chem. 1997;272:5007-5015. Abstract/FREE Full Text 153. Matos P, et al. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J. Biol. Chem. 2003;278:50442-50448. Abstract/FREE Full Text 154. Samper E, et al. Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts. Aging Cell 2003;2:277-285. CrossRefMedlineWeb of ScienceGoogle Scholar 155. Ying L, et al. Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res. 2005;65:9132-9136. Abstract/FREE Full Text 156. Ying L, et al. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res. 2007;67:9286-9293. Abstract/FREE Full Text 157. Hernando E, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430:797-802. CrossRefMedlineWeb of ScienceGoogle Scholar 158. Lee CG, et al. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 2003;22:2592-2603. CrossRefMedlineWeb of ScienceGoogle Scholar 159. Ren J, et al. FAT10 plays a role in the regulation of chromosomal stability. J. Biol. Chem. 2006;281:11413-11421. Abstract/FREE Full Text 160. Lukasiak S, et al. Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 2008;27:6068-6074. CrossRefMedlineWeb of ScienceGoogle Scholar 161. Zhang DW, et al. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. Oncogene 2006;25:2318-2327. CrossRefMedlineWeb of ScienceGoogle Scholar 162. Mills KD, et al. The role of DNA breaks in genomic instability and tumorigenesis. Immunol. Rev. 2003;194:77-95. CrossRefMedlineWeb of ScienceGoogle Scholar 163. Karanjawala ZE, et al. Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. Curr. Biol. 2002;12:397-402. CrossRefMedlineWeb of ScienceGoogle Scholar 164. Opresko PL, et al. Oxidative damage in telomeric DNA disrupts recognition by TRF1 and TRF2. Nucleic Acids Res. 2005;33:1230-1239. Abstract/FREE Full Text 165. von Zglinicki T, et al. Telomeres as biomarkers for ageing and age-related diseases. Curr. Mol. Med. 2005;5:197-203. CrossRefMedlineWeb of ScienceGoogle Scholar 166. San Filippo J, et al. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008;77:229-257. CrossRefMedlineWeb of ScienceGoogle Scholar 167. Lieber MR. The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 2008;283:1-5. Abstract/FREE Full Text 168. Halazonetis TD, et al. An oncogene-induced DNA damage model for cancer development. Science 2008;319:1352-1355. Abstract/FREE Full Text 169. Vafa O, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 2002;9:1031-1044. CrossRefMedlineWeb of ScienceGoogle Scholar 170. Dominguez-Sola D, et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007;448:445-451. CrossRefMedlineGoogle Scholar 171. Taylor WR, et al. Mechanisms of G2 arrest in response to overexpression of p53. Mol. Biol. Cell 1999;10:3607-3622. Abstract/FREE Full Text 172. Menssen A, et al. c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 2007;6:339-352. CrossRefMedlineWeb of ScienceGoogle Scholar 173. Saintigny Y, et al. A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 2001;20:2596-2607. Abstract 174. Plo I, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008;112:1402-1412. Abstract/FREE Full Text 175. Bielas JH, et al. Human cancers express a mutator phenotype. Proc. Natl Acad. Sci. USA 2006;103:18238-18242. Abstract/FREE Full Text 176. Firestein GS, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc. Natl Acad. Sci. USA 1997;94:10895-10900. Abstract/FREE Full Text 177. Andreassi MG, et al. Genetic instability, DNA damage and atherosclerosis. Cell Cycle 2003;2:224-227. MedlineGoogle Scholar 178. Weinberg RA. Coevolution in the tumor microenvironment. Nat. Genet. 2008;40:494-495. CrossRefMedlineWeb of ScienceGoogle Scholar 179. Danish M, et al. Genetic stability of tumor microenvironment. Cancer Biol. Ther. 2008;7:331-332. MedlineWeb of ScienceGoogle Scholar 180. Polyak K, et al. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25:30-38. CrossRefMedlineWeb of ScienceGoogle Scholar 181. Qiu W, et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat. Genet. 2008;40:650-655. CrossRefMedlineWeb of ScienceGoogle Scholar 182. Apetoh L, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007;13:1050-1059. CrossRefMedlineWeb of ScienceGoogle Scholar 183. Shabo I, et al. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int. J. Cancer 2008;123:780-786. CrossRefMedlineWeb of ScienceGoogle Scholar 184. Tamimi RM, et al. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res. 2008;68:18-21. Abstract/FREE Full Text 185. Taskinen M, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 2007;13:5784-5789. Abstract/FREE Full Text 186. Byers RJ, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008;111:4764-4770. Abstract/FREE Full Text 187. Liu R, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 2007;356:217-226. CrossRefMedlineWeb of ScienceGoogle Scholar 188. Seike M, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J. Natl Cancer Inst. 2007;99:1257-1269. Abstract/FREE Full Text

Page 4 of 138« First...«23456»102030...Last »